TaxuCardium Pharmaceuticals Group Inc. announced consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported a net loss of $1,438,000, or $0.16 per basic and diluted share, compared to a net loss of $2,262,000 or $0.36 per basic and diluted share for the same period in 2013, reflecting a reduced loss of $824,000 or 36% arising from lowered research and development costs and general and administrative expenses. Loss from operations was $1,438,489 against $1,975,253 a year ago.

Net loss per share basic and diluted from continued operations was $0.16 against $0.31 a year ago. Non-GAAP net loss was $932,324 or $0.10 per basic and diluted share against net loss of $2,221,605 or $0.35 per basic and diluted share a year ago.